Clinical Trial

Personalised Immunotherapy Platform

Study acronym: PIP-PREDICT
Recruiting
View on ClinicalTrials.gov →
Summary
This is a non-interventional study to prospectively test a suite of predictive biomarker models of immunotherapy resistance in patients with melanoma, non-melanoma skin cancers and other solid tumours. The study will evaluate the documentation, processes, accuracy and utility of the predictive biomarker model in clinical practice.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-31; most recent amendment 2025-09-12.
Trial Details
NCT Number NCT06536257
Lead Sponsor Melanoma Institute Australia
Conditions Melanoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Merkel Cell Carcinoma, Solid Tumor
Enrollment 1,000 participants
Start Date 2021-06-08
Primary Completion 2027-06-01 (estimated)
Study Completion 2037-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-18